GlassScriptPhysician profile
Humberto Leal Bailey
NPI 1477902229
$14,464.26
in general payments reported to CMS, 2019-2025
24 companies · $710 in 2025
The $710 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $10K · 2021: $822 · 2022: $849 · 2023: $1,053 · 2024: $990 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,642 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,641.67 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $10,000.00 | 2020 | |
| Abbvie INC. | $1,121.82 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $797.79 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Mdd US Operations, LLC | $468.81 | 2023-2025 | Gocovri, Gocovri, Apokyn |
| Emd Serono, INC. | $312.85 | 2022-2024 | Mavenclad |
| Biogen, INC. | $208.17 | 2021-2022 | |
| Genentech USA, INC. | $194.16 | 2022-2023 | Ocrevus, Enspryng |
| Lilly USA, LLC | $164.84 | 2022-2025 | Kisunla, Amyvid |
| Acadia Pharmaceuticals INC | $139.79 | 2021 | |
| Pfizer INC. | $135.97 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $125.41 | 2022 | |
| Kyowa Kirin, INC. | $111.08 | 2021-2024 | Nourianz |
| Amneal Pharmaceuticals LLC | $108.24 | 2021-2023 | Rytary |
| Acorda Therapeutics, INC | $103.01 | 2020-2021 | |
| Adamas Pharmaceuticals, INC. | $100.08 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $61.11 | 2022 | |
| Neurocrine Biosciences, INC. | $58.62 | 2021 | |
| Livanova USA, INC. | $52.95 | 2021-2022 | |
| Celgene Corporation | $50.21 | 2022-2024 | Zeposia |
| Merz Pharmaceuticals, LLC | $47.19 | 2021 | |
| Avion Pharmaceuticals | $39.36 | 2022-2023 | Dhivy |
| Ucb, INC. | $23.84 | 2023 | Fintepla |
| Allergan, INC. | $21.80 | 2022 | |
| Medtronic, INC. | $17.16 | 2023 | Sensight |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Humberto Leal Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.